Smart Drug Delivery Systems: Towards Precision and Personalized Medicine

Karishma Rajkumar Jaiswal[1], Dr. H. S. Sawarkar[2]

Dr. Rajendra Gode College of Pharmacy
Amravati, India.

Abstract:
Smart drug delivery systems (SDDS) represent a new era in pharmaceutics, combining responsiveness, targeting, and personalization to overcome the limitations of conventional therapies. By harnessing internal and external stimuli, SDDS enable precise, controlled release of drugs while minimizing systemic toxicity. Platforms such as polymeric nanoparticles, liposomes, hydrogels, and bioinspired carriers are being explored for applications in cancer, neurological disorders, metabolic diseases, infectious diseases, and gene therapies. Despite their promise, challenges in biocompatibility, large-scale manufacturing, regulatory approval, and equitable access remain. This review highlights the principles, platforms, applications, global research landscape, and limitations of SDDS, emphasizing their potential to shape precision and personalized medicine for the future.

Keywords: Smart Drug Delivery Systems (SDDS), Precision Medicine, Personalized Medicine, Nanocarriers.

1. INTRODUCTION

The field of pharmaceutics has always been at the heart of medical progress, bridging chemistry, biology, and engineering to translate therapeutic molecules into clinically useful medicines. Over the past few decades, rapid advances in drug discovery have expanded the portfolio of therapeutic agents from small molecules and peptides to monoclonal antibodies, nucleic acids, and cell-based products [1, 2]. Yet, the delivery of these agents to the right site, at the right concentration, and at the right time remains one of the most pressing challenges in modern healthcare. Conventional drug administration routes—oral tablets, injectables, and topical formulations—while successful in many cases, often suffer from limitations such as poor bioavailability, systemic side effects, patient non-compliance, and lack of precision in targeting diseased tissues. Against this backdrop, smart drug delivery systems (SDDS) have emerged as one of the most transformative innovations in pharmaceutics [3, 4]. These systems integrate advances in nanotechnology, biomaterials, polymer science, and biomedical engineering to create platforms capable of responding to specific biological or external stimuli [4, 5]. Unlike conventional dosage forms, smart carriers can sense microenvironmental cues (such as pH, redox gradients, enzyme activity) or be activated by external triggers (such as light, ultrasound, or magnetic fields), enabling them to release drugs in a spatiotemporally controlled manner [6, 7]. The promise of these systems lies not only in improving therapeutic efficacy and safety but also in aligning with the goals of precision and personalized medicine a paradigm shift that seeks to tailor treatments to individual patient profiles based on genetics, lifestyle, and disease characteristics.

The urgency for innovation in drug delivery stems from both scientific and societal pressures. Globally, the burden of chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions continues to rise, placing immense strain on healthcare systems [8, 9]. Many of these diseases require long-term therapy with agents that are potent but often associated with systemic toxicity. For example, chemotherapeutic drugs can destroy healthy tissues alongside malignant cells, while immunosuppressive agents for autoimmune disorders leave patients vulnerable to infections. Traditional delivery strategies frequently fail to maintain drug concentrations within the narrow therapeutic window, oscillating between sub-therapeutic and toxic levels. Moreover, the advent of biopharmaceuticals such as monoclonal antibodies, RNA therapeutics, and gene-editing tools has created new delivery challenges [8, 10].



Fig.1 Smart drug delivery system

These molecules are often unstable in the systemic circulation, poorly permeable across biological barriers, and susceptible to rapid clearance. Without advanced delivery platforms, their full therapeutic potential remains unrealized. In this sense, SDDS are not merely incremental improvements but a necessity to unlock the benefits of next-generation therapies. The COVID-19 pandemic further highlighted this need, as lipid nanoparticles enabled the successful delivery of mRNA vaccines, arguably one of the most striking proofs-of-concept for smart nanocarriers in modern medicine [11, 12]. The opportunities offered by SDDS are multifaceted. At a fundamental level, they provide solutions to long-standing issues of bioavailability, targeting, and controlled release. Stimuli-responsive systems, for instance, can remain inert during circulation but rapidly release their cargo in response to tumor acidity or enzyme overexpression. This reduces off-target effects while enhancing drug accumulation at the disease site. Similarly, externally triggered systems allow clinicians to modulate therapy in real time, offering a degree of precision that was previously unattainable. From a clinical perspective, SDDS opens the door to personalized medicine [13, 14]. By integrating diagnostic and therapeutic functions into a single platform—so-called “theranostic systems”—these carriers can both monitor disease progression and deliver therapy, enabling feedback-controlled interventions. Advances in genomics and artificial intelligence further amplify this potential by allowing patient-specific optimization of delivery strategies. For example, nanoparticle formulations can be customized to exploit genetic variations in metabolism or receptor expression, ensuring that therapies are not only effective but also tailored to the unique biology of each patient [15, 16]. Economically, the opportunities are equally compelling. The global smart drug delivery market is projected to grow at double-digit rates, driven by the pharmaceutical industry’s demand for differentiated products, the rising cost of drug development, and the push for value-based healthcare. In addition, SDDS may reduce overall treatment costs by decreasing hospitalization, minimizing adverse effects, and improving patient adherence.

At the research frontier, diverse strategies are being pursued to realize the promise of SDDS. Polymeric nanoparticles and micelles remain among the most studied systems due to their versatility, biocompatibility, and ability to incorporate both hydrophilic and hydrophobic drugs [17, 18]. Advances in synthetic chemistry have yielded “smart polymers” capable of responding to multiple stimuli simultaneously, thus allowing highly selective drug release [19, 20]. Liposomes and lipid-based carriers continue to be widely explored, especially after their successful clinical application in vaccines and anticancer drugs. Current research is focused on surface modification with targeting ligands, PEGylation for stealth properties, and hybridization with inorganic nanoparticles to enhance functionality. Hydrogels, with their tunable swelling and degradation properties, are increasingly used for localized delivery in wound healing, tissue engineering, and implantable devices. Stimuli-responsive hydrogels that release drugs in response to glucose levels are being investigated for diabetes management, while thermosensitive gels are explored for minimally invasive injection. A particularly exciting direction involves bioinspired carriers, such as exosomes and cell membrane-coated nanoparticles, which exploit natural biological pathways for immune evasion and efficient tissue penetration. These systems are at the intersection of nanotechnology and synthetic biology, holding immense potential for future clinical translation.

Globally, smart drug delivery has become a top priority for governments, academic institutions, and industry stakeholders. In the United States, the National Institutes of Health (NIH) and the National Cancer Institute (NCI) are funding projects that integrate nanomedicine with precision oncology [14, 21]. Numerous start-ups and pharmaceutical companies are investing in SDDS, with some systems advancing into Phase II and III clinical trials. In Europe, initiatives under Horizon 2020 and Horizon Europe emphasize nanomedicine and bioinspired drug delivery as part of personalized healthcare. Countries like Germany, the UK, and Switzerland have become hubs for translational research, fostering collaborations between universities, hospitals, and biotech firms. In Asia, nations such as China, Japan, and South Korea are rapidly scaling their research capacity, with significant government funding dedicated to nanotechnology-enabled medicine. China, in particular, has seen exponential growth in publications and patents on SDDS, reflecting its strategic focus on biomedical innovation [22-24].

2. EXISTING RESEARCH WORK

In India, pharmaceutical research is gaining momentum, with academic institutes and pharmaceutical companies exploring nanoparticle formulations, transdermal systems, and plant-derived carriers. Government initiatives under the Department of Biotechnology (DBT) and Council of Scientific & Industrial Research (CSIR) are encouraging translational projects aimed at affordable smart therapeutics for cancer, tuberculosis, and metabolic diseases. While challenges such as infrastructure and regulatory pathways remain, the country is positioning itself as a contributor to the global SDDS landscape. A rich body of literature demonstrates the growing maturity of SDDS. For instance, Mura and colleagues (2019) highlighted the broad spectrum of stimuli-responsive nanocarriers under development, from pH-sensitive micelles to enzyme-activated prodrug systems. Torchilin (2020) emphasized the translation of smart nanocarriers into real-world therapies, noting both successes and limitations. Sun et al. (2020) provided a comprehensive review of intelligent nanomedicine systems for cancer therapy, demonstrating how multi-functional platforms integrate imaging, targeting, and therapy.

Hydrogels have been reviewed extensively by Wang et al. (2021), who underscored their utility in both localized drug delivery and tissue engineering. Bioinspired approaches were covered by Zhang et al. (2023), who argued that exosomes represent a paradigm shift in smart delivery by leveraging natural communication pathways between cells. Meanwhile, Peer et al. (2021) emphasized the broader role of nanocarriers in precision medicine, connecting advances in drug delivery to the overarching goals of individualized healthcare. Together, these works illustrate that while significant progress has been made, challenges remain in terms of large-scale manufacturing, reproducibility, and regulatory acceptance. Bridging the gap between laboratory innovation and clinical application requires not only scientific advances but also policy support, interdisciplinary collaboration, and public trust.

3. PRINCIPLES OF SMART DRUG DELIVERY SYSTEMS

The guiding principle of smart drug delivery systems (SDDS) is to move beyond passive transportation of medicines toward an intelligent, responsive, and patient-focused approach. Unlike conventional dosage forms that release drugs in a fixed and often uncontrolled manner, SDDS are designed to respond to specific biological or external triggers. This responsiveness allows them to deliver the right dose at the right place and the right time, minimizing side effects while maximizing therapeutic outcomes. At the core of SDDS lies the concept of stimulus-responsiveness. Internal stimuli, such as changes in pH, enzyme activity, temperature, or redox conditions, often reflect pathological states like tumors or inflammation.

By exploiting these natural signals, smart carriers can selectively release their payload where it is most needed. External stimuli, including light, ultrasound, magnetic fields, or electrical pulses, offer clinicians an additional layer of control, enabling on-demand activation of drug release.



Fig. 2 Principles of SDDS

Another fundamental principle is targeted delivery. Smart carriers can be engineered with ligands or antibodies that recognize disease-specific markers, allowing precise homing of therapeutics to affected tissues while sparing healthy cells. This not only enhances efficacy but also improves the patient's quality of life by reducing systemic toxicity. Finally, SDDS embodies the principle of integration with personalized medicine. By tailoring drug delivery strategies to the genetic, physiological, and lifestyle profiles of individual patients, these systems represent a step toward truly individualized care. They are not just vehicles of drugs but enablers of a holistic, patient-centered healthcare model. In essence, smart drug delivery systems rest on three humanitarian pillars: responsiveness, targeting, and personalization. Together, these principles are redefining pharmaceutics from a discipline of formulations to a science of precision healing.

4. TYPES OF SMART DRUG DELIVERY PLATFORMS

Smart drug delivery systems (SDDS) are not defined by a single material or technology, but rather by a family of platforms designed to meet diverse therapeutic needs. Each platform brings unique advantages, challenges, and opportunities for integration into personalized medicine.

4.1 Polymeric Nanoparticles and Micelles

Polymeric carriers are among the most versatile smart delivery systems. Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) or polyethylene glycol (PEG) can form nanoparticles or micelles that encapsulate drugs and protect them from degradation. Their chemical tunability allows researchers to engineer responsiveness to pH, temperature, or redox conditions. Polymeric micelles, for instance, can carry hydrophobic drugs within their core and release them selectively in tumor microenvironments, offering improved solubility and precision.



Fig. 3 Smart drug delivery mechanism

4.2 Liposomes and Lipid-Based Carriers

Liposomes are spherical vesicles composed of lipid bilayers, widely recognized for their biocompatibility and clinical success. Lipid-based carriers gained global attention through their role in mRNA vaccines during the COVID-19 pandemic. Smart modifications, such as ligand decoration for active targeting or stimuli-sensitive lipids for triggered release, expand their applications in oncology, infectious diseases, and gene therapy.

4.3 Hydrogels and Implantable Devices

Hydrogels are three-dimensional networks of hydrophilic polymers capable of retaining large amounts of water. Their soft, tissue-like structure makes them ideal for localized and sustained delivery. Stimuli-responsive hydrogels can swell or degrade in response to glucose, temperature, or enzymes, enabling applications such as glucose-sensitive insulin release or injectable cancer therapies. Implantable hydrogel-based systems are also being explored for long-term management of chronic diseases.

4.4 Bioinspired and Biomimetic Systems

Nature itself offers powerful blueprints for smart delivery. Exosomes, the body's own nanoscale vesicles for intercellular communication, are now harnessed as drug carriers for their ability to evade immune detection and cross biological barriers. Similarly, cell membrane-coated nanoparticles combine synthetic cores with natural surfaces, uniting functionality with stealth. These bioinspired systems represent the next frontier in creating delivery platforms that harmonize with the body's biology.

5. MECHANISMS OF TARGETING AND CONTROLLED RELEASE

A central feature that distinguishes smart drug delivery systems (SDDS) from traditional formulations is their ability to deliver medicines precisely where and when they are needed. This is achieved through two interconnected principles: targeting and controlled release. Targeting mechanisms ensure that therapeutic agents accumulate preferentially at diseased sites while sparing healthy tissues. In passive targeting, carriers exploit physiological differences such as the enhanced permeability and retention (EPR) effect seen in tumors, where leaky vasculature allows nanoparticles to concentrate. In active targeting, delivery vehicles are decorated with ligands, antibodies, or peptides that recognize and bind to disease-specific receptors. For instance, folate-conjugated nanoparticles can selectively bind to folate receptors overexpressed in certain cancers, improving cellular uptake.

Controlled release mechanisms complement targeting by regulating when and how much of the drug is released. Stimuli-responsive systems are at the forefront of this innovation. Internal triggers—like acidic pH in tumor tissues, redox gradients inside cells, or disease-specific enzymes—can trigger drug release in localized environments. External stimuli, including light, ultrasound, magnetic fields, or heat, provide physicians with real-time control, allowing on-demand activation of therapy. Such dual control not only enhances therapeutic efficiency but also reduces systemic toxicity and side effects.

6. APPLICATIONS OF SMART DRUG DELIVERY SYSTEMS

The true value of smart drug delivery systems (SDDS) lies in their wide-ranging applications across medicine. By offering targeted, responsive, and patient-centered therapies, these systems are revolutionizing how we approach complex diseases.

6.1 Cancer Therapy

Cancer remains the most explored field for SDDS due to the limitations of conventional chemotherapy. Smart nanoparticles, liposomes, and polymeric micelles exploit tumor-specific triggers such as acidity or enzyme overexpression to release drugs selectively at cancer sites. Active targeting with ligands or antibodies further enhances tumor localization. Beyond treatment, theranostic platforms combine imaging and therapy, enabling real-time monitoring of tumor progression and drug response.

6.2 Neurological and CNS Disorders

Crossing the blood–brain barrier (BBB) is one of the most formidable challenges in neurology. Smart carriers such as lipid nanoparticles, exosomes, and magnetic nanocarriers are being engineered to penetrate the BBB and deliver drugs for conditions like Alzheimer's disease, Parkinson's disease, and brain tumors. Stimuli-responsive systems allow controlled release within delicate brain tissues, minimizing systemic toxicity.

6.3 Metabolic Diseases

For conditions such as diabetes, SDDS provides life-changing opportunities. Glucose-responsive hydrogels and nanoparticles can adjust insulin release in real time, mimicking physiological feedback and reducing the burden of frequent dosing. These platforms aim to transform disease management from reactive treatment to proactive, self-regulating care.



Fig. 4 Application of smart drug delivery

6.4 Infectious Diseases and Vaccines

The success of lipid nanoparticles in delivering mRNA vaccines during the COVID-19 pandemic highlighted the potential of SDDS in infectious disease management. Such systems improve the stability of fragile nucleic acids, enhance immune response, and can be rapidly adapted for emerging pathogens.

6.5 Gene and RNA Therapies

The future of personalized medicine increasingly relies on nucleic acid-based therapies. Smart delivery vehicles protect RNA and DNA from degradation, facilitate cellular uptake, and release them in targeted tissues. This opens pathways for treating genetic disorders, rare diseases, and even personalized cancer immunotherapies.

7. CHALLENGES AND LIMITATIONS

Despite their transformative potential, smart drug delivery systems (SDDS) face significant challenges that hinder their broad clinical translation. These limitations stem from biological, technological, regulatory, and economic factors that must be addressed before SDDS can become mainstream in healthcare.



Fig. 5 Challenges of SDDS

7.1 Biocompatibility and Safety

Ensuring that carriers are safe, non-toxic, and biodegradable remains a pressing concern. Nanoparticles and synthetic polymers may accumulate in organs, raising long-term safety questions. For bioinspired systems, such as exosomes or membrane-coated particles, issues of immunogenicity and reproducibility are equally important.

7.2 Manufacturing and Scalability

While laboratory-scale synthesis allows precise engineering, producing smart carriers consistently at an industrial scale is complex and costly. Achieving uniform particle size, drug loading, and release profiles on a mass-production level is a formidable barrier, limiting accessibility.

7.3 Biological Barriers

Crossing complex biological barriers, such as the blood–brain barrier or dense tumor stroma, remains difficult. Even when carriers reach the target site, controlled release may be hampered by unpredictable patient physiology or microenvironmental variability.

7.4 Regulatory and Ethical Hurdles

Regulatory frameworks for nanomedicine and smart delivery systems are still evolving. Demonstrating safety, efficacy, and quality in clinical trials is time-consuming and resource-intensive. Ethical concerns, particularly around personalized approaches using genetic or molecular data, also demand careful navigation.

7.5 Economic and Accessibility Issues

Advanced delivery systems often involve costly materials and processes, making them less accessible in low- and middle-income countries. This raises concerns about global health equity, as patients in resource-limited settings may be excluded from life-saving innovations.

8. CONCLUSION

The evolution of smart drug delivery systems (SDDS) marks a transformative moment in pharmaceutics and healthcare. By integrating responsiveness, targeting, and personalization, these systems promise to overcome the shortcomings of conventional drug delivery and align therapy with the unique needs of each patient. From oncology to neurology, from metabolic disorders to infectious diseases, SDDS are reshaping how medicine is designed, delivered, and experienced.

Yet, the journey from laboratory innovation to clinical reality is far from straightforward. Challenges of biocompatibility, large-scale manufacturing, regulatory approval, and equitable access remain significant barriers. Addressing these hurdles requires collaborative efforts between scientists, clinicians, policymakers, and industry leaders. More importantly, it demands a commitment to ensure that the benefits of these advanced technologies are not confined to privileged populations but are accessible to patients across the globe. The promise of SDDS lies not only in their technological sophistication but also in their humanitarian vision: treatments that are smarter, safer, and more compassionate. As research advances, the integration of artificial intelligence, bioinspired materials, and personalized genomic data will further refine these platforms, bringing us closer to a future where medicines are no longer one-size-fits-all but are tailored with precision and empathy.

REFERENCES:

[1] P. Sanchez-Moreno, J.L. Ortega-Vinuesa, J.M. Peula-Garcia, J.A. Marchal, H. Boulaiz, Smart drug-delivery systems for cancer nanotherapy, Current drug targets 19(4) (2018) 339-359.

[2] A.D. Sezer, Smart drug delivery system, BoD–Books on Demand2016.

[3] M.I. Khan, M.I. Hossain, M.K. Hossain, M. Rubel, K. Hossain, A. Mahfuz, M.I. Anik, Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review, ACS applied bio materials 5(3) (2022) 971-1012.

[4] L. Păduraru, A.-D. Panainte, C.-A. Peptu, M. Apostu, M. Vieriu, T. Bibire, A. Sava, N. Bibire, Smart Drug Delivery Systems Based on Cyclodextrins and Chitosan for Cancer Therapy, Pharmaceuticals 18(4) (2025) 564.

[5] P. Zhang, J. Pan, S. Lin, B. Peng, C. An, J. Zhang, L. Xu, Y. Lai, H. Yu, Z. Xu, Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors, Advanced Drug Delivery Reviews (2025) 115620.

[6] S. Selim, M.S. Almuhayawi, S.K. Al Jaouni, M. Harun-Ur-Rashid, Synthetic Biology Innovations in Designing Cellulose-Based Smart Drug Delivery Systems, BioResources 20(2) (2025).

[7] D. Shi, X. Wang, Y. Deng, H. Zhou, Y. Wang, P.K. Chu, J. Li, Smart micro/nanorobots for drug delivery in the brain, Progress in Materials Science 155 (2026) 101533.

[8] K.T.K. Reddy, A.S. Reddy, Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview, Cellular, Molecular and Biomedical Reports 5(1) (2025) 13-27.

[9] Z. Guo, Y. Xiao, W. Wu, M. Zhe, P. Yu, S. Shakya, Z. Li, F. Xing, Metal–organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives, Journal of Nanobiotechnology 23(1) (2025) 157.

[10] A. Pareek, D. Kumar, A. Pareek, M.M. Gupta, Advancing cancer therapy with quantum dots and other nanostructures: a review of drug delivery innovations, applications, and challenges, Cancers 17(5) (2025) 878.

[11] B. Kallepalli, U. Garg, N. Jain, R. Nagpal, S. Malhotra, T. Tiwari, S. Kaul, U. Nagaich, Intelligent drug delivery: pioneering stimuli-responsive systems to revolutionize disease management-an in-depth exploration, Current Drug Delivery 22(2) (2025) 195-214.

[12] X. Bian, L. Zhou, Z. Luo, G. Liu, Z. Hang, H. Li, F. Li, Y. Wen, Emerging delivery systems for enabling precision nucleic acid therapeutics, ACS nano 19(4) (2025) 4039-4083.

[13] Y. Wang, W. Shao, J. Lin, S. Zheng, Intelligent Drug Delivery Systems: A Machine Learning Approach to Personalized Medicine, (2025).

[14] M. El-Tanani, S.M. Satyam, S.A. Rabbani, Y. El-Tanani, A.A. Aljabali, I. Al Faouri, A. Rehman, Revolutionizing drug delivery: The impact of advanced materials science and technology on precision medicine, Pharmaceutics 17(3) (2025) 375.

[15] S.A. Ramadhan, D.S. Ali, Innovations in Core–Shell Nanoparticles: Advancing Drug Delivery Solutions and Precision Medicine, OMICS: A Journal of Integrative Biology 29(3) (2025) 73-86.
[16] Z. Izadiyan, M. Misran, K. Kalantari, T.J. Webster, P. Kia, N.A. Basrowi, E. Rasouli, K. Shameli, Advancements in liposomal nanomedicines: Innovative formulations, therapeutic applications, and future directions in precision medicine, International Journal of Nanomedicine (2025) 1213-1262.
[17] S. Abolhassani, R. Fattahi, F. Safshekan, J. Saremi, E. Hasanzadeh, Advances in 4D bioprinting: The next frontier in regenerative medicine and tissue engineering applications, Advanced Healthcare Materials 14(4) (2025) 2403065.
[18] J.-J. Du, R.-Y. Zhang, S. Jiang, S. Xiao, Y. Liu, Y. Niu, W.-X. Zhao, D. Wang, X. Ma, Applications of cell penetrating peptide-based drug delivery system in immunotherapy, Frontiers in Immunology 16 (2025) 1540192.
[19] Q. Yu, Z. Tian, G. Li, Y. Yang, X. Chen, D. Wang, W. Peng, R. Liu, H. Gu, X. Yue, Multifunctional composite capsules in drug delivery systems: bridging pharmaceutical and biomedical applications, Advanced Composites and Hybrid Materials 8(1) (2025) 118.
[20] S. Yan, Y. Gan, H. Xu, H. Piao, Bacterial carrier-mediated drug delivery systems: A promising strategy in cancer therapy, Frontiers in Bioengineering and Biotechnology 12 (2025) 1526612.
[21] R.L.F. Melo, D. Nascimento Dari, F.I. da Silva Aires, F. Simão Neto, T.M. Freire, B.C.C. Fernandes, P.B.A. Fechine, J.M. Soares, J.C. Sousa dos Santos, Global advancements in bioactive material manufacturing for drug delivery: A comprehensive study, ACS omega 10(1) (2025) 1207-1225.
[22] W. Graham, M. Torbett-Dougherty, A. Islam, S. Soleimani, T.A. Bruce-Tagoe, J.A. Johnson, Magnetic nanoparticles and drug delivery systems for Anti-Cancer applications: A review, Nanomaterials 15(4) (2025) 285.
[23] J. Liu, T. Wang, J. Dong, Y. Lu, The blood–brain barriers: novel nanocarriers for central nervous system diseases, Journal of Nanobiotechnology 23(1) (2025) 146.
[24] S. Zheng, Y. Tu, B. Li, G. Qu, A. Li, X. Peng, S. Li, C. Shao, Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges, Journal of Translational Medicine 23(1) (2025) 292.